Guardian Pharmacy Services Inc Cla (GRDN) valuation
Guardian Pharmacy Services Inc Cla P/E ratio history
Guardian Pharmacy Services Inc Cla trades at 39.5 times its earnings over the last twelve months and 29.8 times the earnings analysts expect over the next twelve.
| Fiscal year ended | Price | EPS | P/E | Forward P/E |
|---|---|---|---|---|
| Dec 31, 2025 | $30.09 | $0.77 | 39.1 | 28.5 |
| Dec 31, 2024 | $20.26 | — | n/m | — |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
Guardian Pharmacy Services Inc Cla valuation against its peers
| Company | Market value | P/E | Forward P/E | Price / sales |
|---|---|---|---|---|
| Guardian Pharmacy Services Inc ClaGRDN | $2.58B | 39.5 | 29.8 | 1.8 |
| NeogenNEOG | $2.58B | — | 32.6 | 2.9 |
| Viridian Therapeutics OrsVRDN | $2.54B | — | — | 35.8 |
| Adma BiologicsADMA | $2.65B | 16.3 | 13.1 | 5.2 |
| AxogenAXGN | $2.65B | — | 73.6 | 9.9 |
| Mbx BiosciencesMBX | $2.66B | — | — | — |
| Brookdale Senior LivingBKD | $2.48B | — | — | 0.8 |
| PrecigenPGEN | $2.47B | — | 16.6 | 28.9 |
| Enliven TherapeuticsELVN | $2.69B | — | — | — |
| Peer median | 16.3 | 24.6 | 7.6 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: GRDN financials · GRDN returns
No forecast, no recommendation. This page describes Guardian Pharmacy Services Inc Cla from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.